Skip to main content
Premium Trial:

Request an Annual Quote

Cornell Research Foundation, Salk Institute for Biological Studies Awarded US Patents

Premium
The Cornell Research Foundation of Ithaca, NY, has been awarded US Patent 7,288,405, “Devices and methods for pharmacokinetic-based cell culture system.”
 
The inventors listed on the patent are Michael Shuler, Gregory Baxter, Aaron Sin, Robert Harrison, and Scott Meyers.
 
According to its abstract, the patent provides devices, in vitro cell cultures, systems, and methods for a microscale cell culture analogous device.
 

 
The Salk Institute for Biological Studies has been awarded US Patent 7,286,973, “Method of screening inhibitors of mevalonate-independent isoprenoid biosynthetic pathway.”
 
The inventors listed on the patent are Joseph Noel, Marianne Bowman, and Stephane Richard.
 
The patent provides the structure of the enzyme 4-diphosphocytidyl-2-C-methylerythritol (CDP-ME) synthase, a member of the cytidyltransferase family of enzymes from Escherichia coli, as stated in the abstract. The inventors said that CDP-ME is a critical intermediate in the mevalonate-independent pathway for isoprenoid biosynthesis in a number of prokaryotic organisms, in algae, in the plastids of plants, and in the malaria parasite. Since vertebrates synthesize isoprenoid precursors using a mevalonate pathway, CDP-ME synthase and other enzymes of the mevalonate-independent pathway for isoprenoid production represent attractive targets for the structure-based design of selective antibacterial, herbicidal, and antimalarial drugs.
 
The present invention provides methods for screening for compounds that inhibit enzymes of the mevalonate-independent pathway and pharmaceutical compositions and antibacterial formulations thereof.
 
The patent also discusses methods of inhibiting the enzymes of the pathway and bacterial terpenoid synthesis and methods for treating a subject suffering from a bacterial infection.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.